|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net earnings | |||
| Noncash items: | |||
| Depreciation | |||
| Amortization of intangible assets | |||
| Stock-based compensation expense | |||
| Gain on product line disposition | |||
| Loss on product line dispositions | |||
| Impairment of equity method investment | |||
| Impairments and other charges | |||
| Change in deferred income taxes | |||
| Change in trade accounts receivable, net | |||
| Change in inventories | |||
| Change in trade accounts payable | |||
| Change in prepaid expenses and other assets | |||
| Change in accrued expenses and other liabilities | |||
| Net cash provided by operating activities | |||
| Cash flows from investing activities: | |||
| Cash paid for acquisitions, net of cash acquired | |||
| Payments for additions to property, plant and equipment | |||
| Proceeds from sales of property, plant and equipment | |||
| Proceeds from sale of product lines | |||
| All other investing activities | |||
| Net cash used in investing activities | |||
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock in connection with stock-based compensation | |||
| Net transfers to Former Parent | |||
| Proceeds from borrowings | |||
| Payment of dividends | |||
| Proceeds from borrowings (maturities longer than 90 days) | |||
| All other financing activities | |||
| Net cash used in financing activities | |||
| Effect of exchange rate changes on cash and cash equivalents | |||
| Net change in cash and cash equivalents | |||
| Beginning balance of cash and cash equivalents | |||
| Ending balance of cash and cash equivalents | |||
| Supplemental disclosures: | |||
| Cash interest payments | |||
| Total Taxes Paid |
Loading...